EBL exists to help patients and physicians
make better decisions together.
We are not anti-medication, not anti-supplement, and not anti-physician. We are pro-evidence, pro-transparency, and pro-shared decision-making. In that order.
Most “longevity science” is published by companies that sell the thing they’re explaining.
A supplement brand’s blog will always, structurally, find its own category compelling. A biological-age test company will always conclude you should test your biological age. That isn’t dishonesty, it’s gravity.
EBL grades no product it sells. The grade attaches to the intervention at the dose and form the trial actually administered, never to a brand and never to a bottle borrowing credit from a formulation it does not contain. Every letter carries its PMID PubMed ID: the permanent number the US National Library of Medicine gives a published paper. Each one links to that paper's record on PubMed., and the letter is set before the commercial relationship exists, not after. Revenue comes from memberships and from commissions on device hardware and diagnostic testing, which EBL does not grade. A paid device can still sit under a graded therapy, and where one does, the product says so beside its buy link.
When the honest grade is “the evidence doesn’t support this,” we publish that too. That’s the whole product.
The longevity industry sells answers.
We're more interested in the questions.
Every choice EBL makes (every grade, every listing, every refusal to list) comes back to a small set of questions. These are the ones that govern the platform:
Which supplements actually have human RCT Randomized controlled trial: people are assigned to the treatment or a comparison by chance, so the groups differ only in what they received. It is the design that can show cause and effect. evidence, and which only have mechanism, animal data, or marketing?
EBL grades A through D using human trial data only. No animal studies, no mechanism speculation, no commercial pressure on grades. The grade is the standard. A grade tells you the strength of the published human evidence, not whether a supplement is right for you. That decision stays between you and your clinician.
Could your medication be depleting the very nutrient you're now worried about?
Statins deplete CoQ10. Metformin lowers B12. PPIs reduce magnesium. EBL maps 136 medication-nutrient depletions A fall in a nutrient's level caused by a medication, for example through reduced absorption or increased loss. across 50 medications, not to stop your medication, but to help you and your physician have a more complete conversation about it.
What's the actual NNT Number needed to treat: how many people must receive a treatment for one of them to benefit, compared with the control group., how many people need to take this for one to benefit?
"Statistically significant Unlikely to be explained by chance alone at the threshold the study set. It says nothing about whether the difference is large enough to matter." doesn't mean "clinically meaningful." EBL surfaces NNT (number needed to treat) and NNH (number needed to harm) so the size of the effect is visible, not buried.
Which of your biomarkers A measurable sign in the body, such as a blood test value, used to track a condition or the effect of a treatment. are worth retesting, and when does the literature say to recheck?
An intervention without a retest is a guess. EBL's Smart Retest Guide maps each marker to its evidence-based retest cadence, so you know whether the change you made actually worked.
Where does the evidence end, and where does the wishful thinking start?
Most of the longevity industry blurs this line. EBL draws it sharply: human RCT evidence is one thing; promising mechanism is another; brand-driven marketing is a third. We will tell you which is which, even when it costs us affiliate revenue.
How do we equip patients and physicians to make the decision together, rather than for each other?
EBL's patient-handoff sheets, medication discussion guides, and PMID-cited references exist so the conversation between a patient and their physician is grounded in the same evidence. That's the deepest form of respect for both.
Was the exact dose and form in this product the one actually studied, or is the brand borrowing credit from a different formulation?
A 600 mg curcumin capsule does not inherit the evidence of an 1,800 mg piperine-paired formulation. EBL grades the form and dose that was actually tested, not the category. Products that claim a benefit on the strength of a different formulation's research get flagged, not credited.
When a drug has strong evidence for a patient's specific risk profile, EBL says so plainly. Statins in secondary prevention save lives. Metformin in type 2 diabetes is a foundational therapy. GLP-1 agonists in obesity-related metabolic disease are transforming outcomes.
EBL's role is not to argue against these prescriptions. It is to make sure the patient understands the absolute benefit for their risk level, the side effects worth watching, the nutrients the medication may deplete, and the labs worth tracking. EBL is designed to make your physician's prescription work better, not to second-guess it.
EBL holds supplements to the same evidence standard as medications. A supplement with weak evidence gets a weak grade, regardless of how popular it is. A supplement with strong evidence for a specific outcome gets a strong grade for that outcome, and a weak grade for the outcomes it doesn't address.
We grade the evidence for an intervention at the form and dose the trials used, never a brand. Not by marketing, not by sponsorship, and not by popularity.
A number without context is not transparency. EBL does not just show you numbers; it explains what a number means, how confidently the literature supports it, how it was measured, and what questions it tends to raise in the exam room. It does not tell you what to do about it, and it does not tell you what to take, what to stop, or what to avoid. NNT, evidence grades, and depletion maps are inputs to a decision, never the decision itself. That decision belongs to you and the licensed clinician who has actually examined you, and our job ends at giving the two of you a straight account of the evidence.
×EBL will not tell anyone to stop a prescribed medication.
×EBL will not change an evidence grade because of an anecdote, a sponsor, or a popular opinion.
×EBL will not pretend that absence of evidence is evidence of absence. But it will not pretend the reverse either.
Your physician decides. EBL prepares you for that conversation with the best evidence available, graded honestly, presented clearly, and updated as the science evolves.
Questions about how EBL grades evidence? See The EBL Method or Our Disclosures & COI Policy.